Trump's pharma threats send stocks downwards

11 January 2017
trump-big

Ever since his surprise US presidential election win in November, what Donald Trump’s Presidency might mean for pharma has been the subject of plenty of guesswork.

Within minutes of his first press conference as President-elect on Wednesday, Mr Trump gave his clearest indication yet – and pharma stocks reacted according.

Mr Trump called for ‘bidding procedures’ for the drug industry, saying it has a lot of lobbyists and is “getting away with murder.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical